초록 ▼

The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention

The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.

대표청구항 ▼

1. A method of treating pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, wherein the nanoparticles in the composition have an average diameter of

1. A method of treating pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, wherein the individual has progressed on a gemcitabine-based therapy, and wherein the gemcitabine-based therapy has stopped for at least 6 months when initiating administration of the effective amount of the nanoparticle composition. 2. The method of claim 1, wherein the progression is within less than about 12 months. 3. A method of treating resistant pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, wherein the individual was subjected to a prior gemcitabine-based therapy, and wherein the prior gemcitabine-based therapy has stopped for at least 6 months when initiating administration of the effective amount of the nanoparticle composition. 4. A method of treating recurrent pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, wherein the individual was subjected to a prior gemcitabine-based therapy, and wherein the prior gemcitabine-based therapy has stopped for at least 6 months when initiating administration of the effective amount of the nanoparticle composition. 5. The method of claim 1, wherein the gemcitabine-based therapy further comprises erlotinib. 6. The method of claim 1, wherein the gemcitabine-based therapy is monotherapy. 7. The method of claim 1, further comprising administering to the individual an effective amount of another agent. 8. The method of claim 7, wherein the other agent is selected from the group consisting of 5-fluororuracil, erlotinib, gefitnib, marimastat, irinotecan, tipifarnib, pemetrexed, exatecan, capecitabine, raltitrexed, cetuximab, bevacizumab, bortezomib, rapamycin, and vandetanib. 9. The method of claim 1, wherein the pancreatic cancer is exocrine pancreatic cancer or endocrine pancreatic cancer. 10. The method of claim 9, wherein the exocrine pancreatic cancer is pancreatic ductal carcinoma. 11. The method of claim 1, wherein the pancreatic cancer is locally advanced pancreatic cancer, unresectable pancreatic cancer, or metastatic pancreatic ductal carcinoma. 12. The method of claim 1, wherein the individual is human. 13. The method of claim 1, wherein levels of serum CA19-9 (carbohydrate antigen 19-9) in the individual are decreased by at least about 50% in comparison to the levels of serum CA19-9 prior to the treatment. 14. The method of claim 3, wherein the gemcitabine-based therapy is monotherapy. 15. The method of claim 3, further comprising administering to the individual an effective amount of another agent. 16. The method of claim 3, wherein the individual is human. 17. The method of claim 4, wherein the gemcitabine-based therapy is monotherapy. 18. The method of claim 4, further comprising administering to the individual an effective amount of another agent. 19. The method of claim 4, wherein the individual is human.